Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention

This article seeks to analyze the clinical trials concerning the newly approved eptinezumab to assess its efficacy, safety, and application to current clinical practice. The Institute of Health US National Library of Medicine Clinical Trials, PubMed, and Cochrane Library databases were searched for...

Full description

Bibliographic Details
Main Authors:	Kelsey Woods Morgan, Kayla Rena Joyner
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-10-01
Series:	SAGE Open Medicine
Online Access:	https://doi.org/10.1177/20503121211050186

Similar Items

Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine
by: Susan Pederson, et al.
Published: (2021-10-01)

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody
by: Larisa A. Dobrynina, et al.
Published: (2023-06-01)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019-04-01)

Atogepant for the prevention of episodic migraine in adults
by: Maranda Paige Switzer, et al.
Published: (2022-10-01)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
by: Simona Sacco, et al.
Published: (2019-01-01)

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
by: Simona Sacco, et al.
Published: (2022-06-01)

Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
by: Simona Sacco, et al.
Published: (2019-05-01)

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
by: Antun R. Pavelic, et al.
Published: (2022-12-01)

Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison
by: Jiajie Lu, et al.
Published: (2021-05-01)

Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
by: Jean Schoenen, et al.
Published: (2023-08-01)

The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
by: Min Hou, et al.
Published: (2017-04-01)

Placebo response with subcutaneous injections in calcitonin gene-related peptide receptor monoclonal antibody migraine preventative trials – A systematic review and meta-analysis
by: Sasikanth Gorantla, et al.
Published: (2022-08-01)

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
by: Russell Nichols, et al.
Published: (2019-03-01)

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
by: Antoinette MaassenVanDenBrink, et al.
Published: (2018-02-01)

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
by: Varnado OJ, et al.
Published: (2022-03-01)

Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE
by: Richard B. Lipton, et al.
Published: (2023-11-01)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
by: Michal Fila, et al.
Published: (2023-01-01)

Calcitonin gene-related peptide causes migraine aura
by: Haidar M. Al-Khazali, et al.
Published: (2023-09-01)

Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review
by: Pablo Irimia, et al.
Published: (2024-03-01)

Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking
by: Raffi Manoukian, et al.
Published: (2019-04-01)

Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis
by: Xing Wang, et al.
Published: (2022-09-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

Calcitonin gene–related peptide in migraine: from pathophysiology to treatment
by: S. Santos-Lasaosa, et al.
Published: (2022-06-01)

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
by: Nicole Limberg
Published: (2023-06-01)

Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
by: Danuta Szkutnik-Fiedler
Published: (2020-12-01)

Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
by: Wenfang Sun, et al.
Published: (2024-01-01)

Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine
by: Michal Fila, et al.
Published: (2022-05-01)

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
by: Damiana Scuteri, et al.
Published: (2021-09-01)

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention
by: Shuchita Garg, et al.
Published: (2020-01-01)

An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity
by: Edward Griffin, et al.
Published: (2024-04-01)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
by: Altamura C, et al.
Published: (2023-11-01)

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
by: Andrew Blumenfeld, et al.
Published: (2022-07-01)

Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine
by: Yan Jiang, MMed, et al.
Published: (2022-06-01)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
by: Casper Emil Christensen, et al.
Published: (2018-11-01)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
by: Paolo Martelletti, et al.
Published: (2019-05-01)

How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
by: Cindy Tiseo, et al.
Published: (2019-05-01)

Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023-04-01)

Monoclonal CGRP- (R) antibodies for the prevention of migraine
by: Uwe Reuter
Published: (2023-03-01)

Efficacy and safety of eptinezumab for migraine: A systematic review and meta-analysis
by: Yi Zhong, et al.
Published: (2023-01-01)

Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
by: Peter Holzer, et al.
Published: (2022-01-01)